Cogstate Limited (ASX:CGS)
Australia · Delayed Price · Currency is AUD | Market Cap | 542.04M +65.7% |
| Revenue (ttm) | 87.98M +14.6% |
| Net Income | 17.19M +17.3% |
| EPS | 0.10 +15.1% |
| Shares Out | 169.92M |
| PE Ratio | 32.89 |
| Forward PE | 25.38 |
| Dividend | 0.04 (1.36%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 879,400 |
| Open | 3.190 |
| Previous Close | 3.190 |
| Day's Range | 3.190 - 3.380 |
| 52-Week Range | 1.750 - 3.380 |
| Beta | 0.21 |
| Analysts | Strong Buy |
| Price Target | 3.57 (+8.51%) |
| Earnings Date | Nov 19, 2026 |
About Cogstate
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide. The company offers digital cognitive assessment, endpoint data quality (rater services), remote assessment, scientific consulting, healthcare cognitive screening, and research and academic collaboration solutions for various therapeutic areas, including Alzheimer’s disease and dementia, preclinical Alzheimer’s disease, pediatrics and rare disease, Parkinson’s disease, multiple sclerosis, s... [Read more]
Financial Performance
In fiscal year 2026, Cogstate's revenue was $60.86 million, an increase of 14.64% compared to the previous year's $53.09 million. Earnings were $11.90 million, an increase of 17.25%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for CGS stock is "Strong Buy." The 12-month stock price target is $3.57, which is an increase of 8.51% from the latest price.
News
Cogstate (ASX:CGS) -- Strong Growth and Market Leadership | Lakehouse Capital Q2 2026
Cogstate (ASX:CGS) -- Strong Growth and Market Leadership | Lakehouse Capital Q2 2026
Cogstate Earnings Call Transcript: H2 2026
FY 2026 delivered record revenue and profit growth, driven by clinical trials expansion, diversification into new neurological indications, and strong channel partnerships. Margin expansion was supported by technology investment and operational leverage, with a robust outlook for FY 2027.
Cogstate Annual report: H2 2026
Cogstate has published its H2 2026 annual report on August 17, 2026.
Cogstate Earnings release: H2 2026
Cogstate released its H2 2026 earnings on August 17, 2026, summarizing the period's financial results.
Cogstate Slides: H2 2026
Cogstate has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 17, 2026.
Cogstate Transcript: Status update
Sales contracts for FY 2026 have reached record levels, driven by diversification into psychiatry, narcolepsy, and rare diseases, supported by digital assessments and strong partnerships. Central rating, AI analytics, and scalable delivery models enhance data quality and efficiency, positioning the company for continued growth.
Cogstate Slides: Status update
Cogstate has posted slides in relation to its latest quarterly earnings report, which was published on June 9, 2026.
Cogstate Earnings Call Transcript: H1 2026
Record sales contracts and strong clinical trial growth drove double-digit revenue and earnings increases, with significant expansion in mood, sleep, and neuro segments. Margins are expected to recover in H2, supported by a robust pipeline, technology investment, and a strong cash position.
Cogstate Quarterly report: H1 2026
Cogstate has published its H1 2026 quarterly earnings report on February 18, 2026.
Cogstate Slides: H1 2026
Cogstate has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 18, 2026.
Cogstate Earnings release: H1 2026
Cogstate released its H1 2026 earnings on February 18, 2026, summarizing the period's financial results.
Cogstate Slides: Investor Presentation
Cogstate has posted slides in relation to its latest quarterly earnings report, which was published on November 24, 2025.
Cogstate Transcript: AGM 2025
Record financial results were achieved with strong revenue and profit growth, driven by diversification into new CNS indications and strategic partnerships. The Board declared a dividend, renewed the employee equity plan, and outlined continued investment in technology and AI. All resolutions were supported by proxies and no major risks or headwinds were reported.
Cogstate Slides: FY 2025
Cogstate has posted slides in relation to its FY 2025 quarterly earnings report, which was published on October 15, 2025.
Cogstate Expands Alzheimer's Disease Leadership with Appointment of Dr. Kaycee Sink, as Chief Medical Officer
Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief ...
Cogstate Announces Formation of Scientific Advisory Board
Leading clinical and scientific experts in neurodegenerative diseases and pharmaceutical research will provide guidance to progress Cogstate's strategy Leading clinical and scientific experts in neuro...